As the world population nears the 8 billion mark, Novartis is celebrating the delivery of 1 billion antimalarial treatments since 1999. That is the equivalent of 1 in 8 people living on our planet!

Standing by people with sickle cell disease and their families

Learn how we’re working with partners like the International Agency for the Prevention of Blindness to eliminate preventable blindness.

The first pan-African Novartis Social Business stakeholder dialogue took place in Kampala, Uganda, on March 20, 2019.

European Medicines Agency (EMA) recently approved two European Novartis sites for commercial CAR-T manufacturing.

The RUXCOVID clinical trial highlights the Novartis commitment to leverage our expertise and resources to support the global response to the COVID-19 pandemic.

September 29 is World Heart Day. For the past six decades, Novartis has been working to advance heart health around the world.

Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.

For over 40 years Novartis has been committed to understanding sickle cell disease and working towards treatment.

Learn how we are shifting from making the patient fit the treatment to making the treatment fit the patient.